Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.53 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 4.87 | |||||
Debt-to-EBITDA | -5.54 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.25 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.7 | |||||
3-Year EBITDA Growth Rate | -27.4 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year FCF Growth Rate | -298.6 | |||||
3-Year Book Growth Rate | -20.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 12.9 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 14.43 | |||||
9-Day RSI | 24.5 | |||||
14-Day RSI | 30.7 | |||||
6-1 Month Momentum % | -8.96 | |||||
12-1 Month Momentum % | 22.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.37 | |||||
Quick Ratio | 7.28 | |||||
Cash Ratio | 6.73 | |||||
Days Inventory | 969.73 | |||||
Days Payable | 581.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | -4.14 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.72 | |||||
Operating Margin % | -50.1 | |||||
Net Margin % | -49.54 | |||||
FCF Margin % | -44.68 | |||||
ROE % | -100.54 | |||||
ROA % | -13.23 | |||||
ROIC % | -75.58 | |||||
ROC (Joel Greenblatt) % | -112.19 | |||||
ROCE % | -11.06 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.23 | |||||
PB Ratio | 19.22 | |||||
Price-to-Tangible-Book | 19.24 | |||||
EV-to-EBIT | -17.44 | |||||
EV-to-Forward-EBIT | -9.05 | |||||
EV-to-EBITDA | -18.94 | |||||
EV-to-Forward-EBITDA | -9.33 | |||||
EV-to-Revenue | 6.36 | |||||
EV-to-Forward-Revenue | 8.41 | |||||
EV-to-FCF | -14.31 | |||||
Price-to-Projected-FCF | 13.69 | |||||
Price-to-Median-PS-Value | 0.65 | |||||
Earnings Yield (Greenblatt) % | -5.73 | |||||
FCF Yield % | -6.06 |